The role of p.Val444Ala variant in the ABCB11 gene and susceptibility to biliary atresia in Vietnamese patients

Nguyen Van Tung, MSc\textsuperscript{a,b,}\textsuperscript{*}, Nguyen Thi Kim Lien, PhD\textsuperscript{a}\textsuperscript{,}\textsuperscript{e}, Nguyen Pham Anh Hoa, PhD, MD\textsuperscript{a}\textsuperscript{,}\textsuperscript{d}, Nguyen Thi Phuong Mai, PhD\textsuperscript{c}, Pham Thi Hai Yen, MSc, MD\textsuperscript{e}\textsuperscript{,}\textsuperscript{d}, Nguyen Pham Anh Hoa, PhD, MD\textsuperscript{c}\textsuperscript{,}\textsuperscript{d}, Nguyen Huy Hoang, PhD\textsuperscript{a}\textsuperscript{,}\textsuperscript{b}\textsuperscript{,}\textsuperscript{*}\textsuperscript{,}\textsuperscript{e}

Editor: Maya Saranathan.

NVT and NTKL contributed equally.

This study was supported by the National Foundation for Science and Technology Development, Vietnam (NAFOSTED, grant no. 108.02-2018.305).

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

\textsuperscript{a} Institute of Genome Research, Vietnam Academy of Science and Technology, Vietnam.

\textsuperscript{b} Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Vietnam.

\textsuperscript{c} Vietnam National Children’s Hospital, Ministry of Health, Vietnam.

\textsuperscript{d} Correspondence: Nguyen Huy Hoang, Assoc Prof. PhD. Institute of Genome Research, Vietnam Academy of Science and Technology, 18 - Hoang Quoc Viet str., Cau Giay, Hanoi, Vietnam (e-mail: nhhoang@igr.ac.vn).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Van Tung N, Lien NT, Lan NN, Mai NT, Yen PT, Hoa NP, Hoang NH. The role of p.Val444Ala variant in the ABCB11 gene and susceptibility to biliary atresia in Vietnamese patients. Medicine 2021;100:47 (e28011).

Received: 28 May 2021 / Received in final form: 26 October 2021 / Accepted: 11 November 2021

Abstract

Biliary atresia (BA) is one of the most serious types of obstructive cholangiopathy that occurs in infants. BA can be the cause of death in children under 2 years if untreated early. However, the etiology of the disease is not known. BA is considered to be the result of the destruction of the bile duct system including the accumulation of bile acids. The bile salt export pump, a transporter protein encoded by the \textit{ABCB11} gene, plays the main role in the exportation and accumulation of bile acids. The p.Val444Ala variant in this gene is known to be associated with many cholestatic diseases. However, to date no study have been performed to evaluate the association of this variant with susceptibility to the risk of BA. In this study, we aimed to identify the frequency of p.Val444Ala variant and the risk of BA in Vietnamese patients.

In our study, the frequency of alleles c.1331T>C (p.Val444Ala, rs2287622) in the \textit{ABCB11} gene was investigated the first time in the patients with BA. The results showed that CC and TC genotypes were significantly different between BA patients and healthy people (\(P<.01\)), and the C allele was associated with an increased risk of BA (odds ratio = 2.47; 95% confidence interval: 1.84–3.32; \(P<.01\)). The initial results of clinical, biochemical, and genetic analysis in our study suggested that the p.Val444Ala variant in the \textit{ABCB11} gene may be a susceptibility factor for the disease in Vietnamese patients with BA. These results provided new insights into the role of this ABCB11 variant in the pathogenesis of BA.

**Abbreviations:** BA = biliary atresia, BSEP = bile salt export pump, CI = confidence interval, DNA = deoxyribonucleic acid, HPE = hepatoportoenterostomy, OR = odds ratio, PCR = polymerase chain reaction, PFIC = progressive familial intrahepatic cholestasis.

**Keywords:** ABCB11 gene, biliary atresia, p.Val444Ala variant, the risk factor, Vietnamese patients

1. Introduction

Biliary atresia (BA) is one of the neonatal cholestatic diseases due to biliary fibrosis and obstruction of the intra- and extra-hepatic biliary tract, which reaches up to 1/5000 Asian infants but only 1/18,000 Caucasian infants.\cite{1} If undiagnosed and untreated, BA can lead to death within the first 2 years of age. However, diagnosis of BA is a great challenge and early diagnosis will limit the progression to cirrhosis.\cite{2} For infants with BA, if detected in the first 3 months of life, the Kasai hepatportoenterostomy (HPE) is performed to restore bile flow and half of the children have the chances of survival after 2 years of age.\cite{3} In many patients, the origination of failure in Kasai HPE is not clear, it might be due to progression of intrahepatic bile duct damages and decline repair of bile duct epithelial cells. Also, to prolong life, 70% to 80% of BA patients need liver transplantation.\cite{4}

The etiology and pathogenic mechanism of the BA have not been fully understood. BA is a multi-cause disease, in which, the genetic cause plays a certain role in the formation of the disease.\cite{4,5} To date, many genes have been identified in association with BA.\cite{6-10} Besides that, variants in some genes have also been identified to increase the risk of BA.\cite{11-17} BA is also considered to be a result of several pathogenic processes leading to ascending obstruction of bile ducts which affects both
the intrahepatic and extrahepatic biliary duct system. The destruction and rapid progression of biliary fibrosis, possibly due to incessant cholestasis and retention of bile components including bile acids. The bile salt export pump (BSEP), a transporter protein encoded by the ABCB11 gene, plays the main role in the exportation of the bile acids from the hepatocyte to the bile ducts. Defects in BSEP synthesis and/or function lead to reduced bile salt secretion and accumulation of bile salts. Based on the existing knowledge, a few studies have worked on the potential role of plasma bile acid levels and the contribution of variant p.Val444Ala (c.1331T>C, rs2287622) of ABCB11 to susceptibility for intrahepatic cholestasis of pregnancy and progressive familial intrahepatic cholestasis (PFIC). Sangkhathat et al performed whole exome sequencing analysis in 20 BA patients and identified 13 rare variants in 9 genes that are associated with the disease: 4 in JAG1 (Alagille syndrome), 2 in MYO5B (PFIC type 6), and one each in ABC2C (Dubin–Johnson syndrome), ABCB11 (PFIC type 2), UG1A1 (Crigler–Najjar syndrome), MLIL2 (Kabuki syndrome), RXF6 (Mitchell–Riley syndrome), ERCC4 (Fanconi anemia), and KCNH1 (Zimmermann–Laband syndrome).

In Vietnam, BA has been reported to be as high as 1 in every 2400 live births. Patients with BA frequently face episodes of biliary tract infections, absorption disorders, delay in physical development, cirrhosis, portal hypertension, and gastrointestinal bleeding. Affected children have irreversible cirrhosis and require liver transplant surgery. Therefore, the study aimed to investigate the potential role of variant p.Val444Ala (c.1331T>C, rs2287622) in the ABCB11 gene in the risk of disease in Vietnamese patients with BA.

2. Materials and methods

2.1. Study subjects

Deoxyribonucleic acid (DNA) was collected from 266 Vietnamese patients who were diagnosed with BA by ultrasonography, biochemical liver function tests, and liver biopsy (Table 1, Fig. 1). The patients underwent Kasai surgery at the age of 2 to 3 months at the Hepatology Department, Vietnam National Children’s Hospital. A control cohort of 150 healthy infants (125 boys and 125 girls aged 2–3 months) was formed.

2.2. Ethics statement

The present study protocol was reviewed and approved by the Institutional Review Board of the Institute of Genome Research, Vietnam Academy of Science and Technology (approval No. 06/QD-NCHG). Informed consent was submitted by all subjects when they were enrolled.

2.3. DNA extraction and genotyping

DNA extraction was performed using the Gene JET Whole Blood Genomic DNA Purification Mini Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s instructions. For genotyping of the variant p.Val444Ala (c.1331T>C, rs2287622) in the ATP-binding cassette, subfamily B (MDR/TAP), member 11 ABCB11 gene, we used the primers included 5'-CACACA-GACACCCAGTATCAACACA-3' as F primer and 5'-CAG-GACAGTCTCAATGATGCTACACCT-3' as R primer. Amplification was carried out using Dream Taq DNA Polymerase (Thermo Fisher Scientific, Waltham, MA). The initial denaturation temperature was 95°C for 4 minutes followed by cycling, including denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and extension at 72°C for 60 seconds, for 30 cycles, and a final extension at 72°C for 5 minutes. A polymerase chain reaction (PCR) product of 333bp contains a cut-off point of HaeIII restriction enzyme was obtained and digested into 2 fragments of different sizes with HaeIII restriction enzyme. The C allele was digested to produce bands of 206 and 127bp in positive samples. While the T allele was not digested in positive samples. And the heterozygous samples formed 3 bands of 333, 206, and 127bp after digested with HaeIII restriction enzyme.

2.4. Statistical analysis

Data were analyzed using the statistical package SPSS version 23 (IBM, New York). Allele distribution of the variant follows Hardy–Weinberg equilibrium was tested using Chi-squared test.
(χ²). Three models (additive, dominant, recessive) were tested for association of the variant p.Val444Ala (c.1331T>C, rs2287622) with susceptibility to the disease. The odds ratio (OR) and 95% confidence interval (CI) were calculated to detect the risk ratio between patients and controls. A 2-tailed test was used for all of the statistical analyses and P-values <.05 were considered statistically significant.

3. Results

In this study, 266 patients were diagnosed with BA. According to the classification of the Japanese Association of Pediatric Surgeons, there were 5 patients with type 1 (obstruction at the level of the common bile duct), 1 patient with type 2 (obstruction at the level of the common hepatic duct), and 260 patients with type 3 (obstruction at the level of porta). Type 3 is the commonest type (3 obstruction at the level of the common bile duct), 1 patient with type 2 (obstruction at the level of the common hepatic duct), and 260 patients with type 3 (obstruction at the level of porta).

Three models of alleles (additive, dominant, and recessive) were performed in statistical analysis. Genotype analysis in Table 3 demonstrates that the occurrence of the C allele was significantly over-represented in BA patients (54.51%) than that in the control group (32.67%) (OR = 2.47, 95% CI = 1.84–3.32, P < .01). In the additive model, a significant difference of genotypes was obtained in both the patient group (78.95%) and the control group with P < 0.01. The frequency of CC genotype differed significantly between the 2 groups and was associated with an increased risk of BA (OR= 5.14, 95% CI = 2.82–9.39, P < .01) compared to the TT genotype. The frequency of TC genotype also differed significantly between the 2 groups (OR= 2.88, 95% CI = 1.81–4.59, P < .01) compared to the TT genotype. Similarly, the CC genotype was linked to an increased BA risk when compared to the genotype TT + TC (OR= 2.79, 95% CI = 1.63–4.79, P < .01) in the recessive model. Moreover, in the dominant model the frequency of combined TC + CC genotypes in the BA patient group (78.95%) was significantly higher than that in the control group (52.00%) (OR = 3.46, 95% CI = 2.24–5.35, P < .01).

4. Discussion

BA is an inflammatory biliary disease in a newborn, characterized by fibrosis and obstruction of intrahepatic and extrahepatic bile ducts. The destruction of the inner and outer bile ducts, the result of unexplained inflammatory processes, leading to fibrosis, progressive biliary obstruction, and cirrhosis of the liver. The destruction and rapid progression of biliary fibrosis, possibly due to incessant cholestasis and retention of bile components including bile acids. Studies based on fibrogenesis and inflammation suggested that these processes contribute to the formation mechanism of the disease and in certain populations, cholestasis may affect the effectiveness of HPE surgery and subsequent restoration of biliary tract function. And the relationship between BA and other cholestatic diseases has been observed.

Besides, the genetic participates in the adaptation and response to cholangiopathies and cholestasis that provide therapeutic

### Table 2

| Genotype | Allele frequency (%) |
|----------|----------------------|
|          | T       | C       |
| Patients | 56 (45.5) | 130 (54.5) |
| Control  | 72 (46.0) | 58 (54.0) |
| Total    | 128 (55.0) | 188 (45.0) |

HWE = Hardy–Weinberg equilibrium was checked by Chi-squared test.

### Table 3

| Genotype | Patients (n=266) | Control (n=150) | OR     | 95% CI         | P-value |
|----------|-----------------|----------------|--------|---------------|---------|
| Additive |                 |                |        |               |         |
| TT       | 56 (21.05%)     | 72 (48.00%)    | 1.00   | 1.81–4.59     | <0.01   |
| TC       | 130 (48.87%)    | 58 (38.67%)    | 2.88   | 2.82–9.39     | <0.01   |
| CC       | 80 (30.08%)     | 20 (13.33%)    | 5.14   |               |         |
| Dominant |                 |                |        |               |         |
| TT       | 56 (21.05%)     | 72 (48.00%)    | 1.00   |               | <0.01   |
| TC + CC  | 210 (78.95%)    | 78 (62.00%)    | 3.46   | 2.24–5.35     | <0.01   |
| Recessive|                 |                |        |               |         |
| TT + TC  | 186 (69.92%)    | 130 (86.67%)   | 1.00   |               | <0.01   |
| CC       | 80 (30.08%)     | 20 (13.33%)    | 2.79   | 1.63–4.79     | <0.01   |
| Alleles  |                 |                |        |               |         |
| T        | 242 (45.49%)    | 202 (67.33%)   | 1.00   |               | <0.01   |
| C        | 290 (54.51%)    | 98 (32.67%)    | 2.47   | 1.84–3.32     | <0.01   |

95% CI = 95% confidence interval of odds ratio, OR = Odds ratio, P-value = calculated by either Fisher exact test or Chi-squared test. P < .05 indicates statistical significance.
targets and genetic screening. Contribution of variant allele of the \textit{ABCB11} gene encodes the BSEP, has been demonstrated to relate to susceptibility to intrahepatic cholestasis in different populations. Variants in the \textit{ABCB11} gene are known associated with extrahepatic BA in Thai patients, intrahepatic cholestasis in pregnancy, and early advanced fibrosis. However, to date, no studies have been performed to evaluate the role of this variant in the susceptibility to BA. Publications have been done in patients with cholestasis, especially in PFIC.

In this study, we selected the patients who were confirmed with BA by Kasai surgery and liver biopsy for genotype analysis. We performed whole exome sequencing of several patients with BA to identify the variants that might be the cause of the disease. However, the variants that were identified in the \textit{ABCC2, ERCC4, GPC1, ICAM1, ITGB2, MYOSB, NOTCH1, NOTCH2, and NOTCH3} genes in these patients (data not shown) are all benign in the ClinVar database. Besides, 2 gene variants (\textit{ABCC2} rs927344 and \textit{MYOSB} rs1815930) have been investigated to find the association with the disease in the BA patients. The variant in the \textit{ABCC2} gene has been identified as a factor of the increasing bilirubin in the blood and a risk factor for cholestasis in pregnancy. The variants in the \textit{MYOSB} gene have been reported as related to biliary anomalies leading to clinical symptoms of BA such as jaundice and intrahepatic cholestasis. \textit{MYOSB} mutations were reported to affect hepatic biliary function, increase the serum bile acid levels, and lead to cholestasis in the patients with or without MVID (micrervilloid inclusion disease). However, the results of genetic analysis (in the \textit{ABCC2} and \textit{MYOSB} genes) in Vietnamese patients showed no correlation between these variants and BA.

Otherwise, the results of variant analysis in the \textit{ABCB11} gene revealed that CC and TC genotypes were significantly different between BA patients and healthy people (\(P<0.01\)), and the C allele was associated with an increased risk of BA (OR = 2.47; 95\% CI: 1.84–3.32; \(P<0.01\)). The frequency of TC \+ CC genotype of variant p.Val444Ala (c.1331T>C, rs2287622) in the \textit{ABCB11} gene was significantly different in Vietnamese patients with BA disease. Although there has been no clear evidence linking this variant with susceptibility to BA, the results of genetic analysis about the genetic correlation of \textit{ABCB11} variant p. Val444Ala with BA raised the hypothesis that cholestasis may be the cause of severe inflammatory cholangiopathy in BA. This variant can closely related to cholestasis and lead to serious damage to the biliary tract that obstructs the biliary tract in the patients. The results revealed an association between the \textit{ABCB11} variant p.Val444Ala and the BA disease risk in Vietnamese patients.

In conclusion, the frequency variant p.Val444Ala in the \textit{ABCB11} gene suggested that the C allele may be related to an increased risk of BA. Our result contributed to the general understanding of the cause of the disease and provided new insight into the role of this variant in the pathogenesis of BA.

Acknowledgments

We are grateful to all patients who participated in this study.

Author contributions

Conceptualization: Nguyen Thi Kim Lien, Nguyen Pham Anh Hoa.

Data curation: Nguyen Thi Phuong Mai, Pham Thi Hai Yen, Nguyen Pham Anh Hoa.

Formal analysis: Nguyen Thi Kim Lien, Nguyen Ngoc Lan.

Funding acquisition: Nguyen Huy Hoang.

Investigation: Nguyen Van Tung, Nguyen Ngoc Lan, Nguyen Thi Phuong Mai, Pham Thi Hai Yen.

Methodology: Nguyen Van Tung.

Software: Nguyen Van Tung.

Writing – original draft: Nguyen Van Tung, Nguyen Thi Kim Lien.

Writing – review & editing: Nguyen Thi Kim Lien, Nguyen Pham Anh Hoa, Nguyen Huy Hoang.

References

[1] Miethke AG, Hupertt SS. Fishing for biliary atresia susceptibility genes. Gastroenterology 2013;144:878–81.
[2] Ghazy RM, Adawy NM, Khedr MA, et al. Biliary atresia recent insight. Egypt Pediatric Assoc Gaz 2018;66:1–8.
[3] Superina R, Magee JC, Brandt ML, et al. The anatomic pattern of biliary atresia identified at time of Kasai hepatoportoenterostomy and early postoperative clearance of jaundice are significant predictors of transplant-free survival. Ann Surg 2011;254:577–85.
[4] Moreira RK, Cabral R, Gowles RA, et al. Biliary atresia: a multidisciplinary approach to diagnosis and management. Arch Pathol Lab Med 2012;136:746–60.
[5] Asai A, Miethke A, Bezerra JA. Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes. Nat Rev Gastroenterol Hepatol 2015;12:342.
[6] Shih HH, Liu TM, Chuang JH, et al. Promoter polymorphism of the CD14 endotoxin receptor gene is associated with biliary atresia and idiopathic neonatal cholestasis. Pediatrics 2005;116:437–41.
[7] Arikan C, Berdeli A, Ogcen F, et al. Positive association of macrophage migration inhibitory factor gene-173GC polymorphism with biliary atresia. J Pediatr Gastroenterol Nutr 2006;42:77–82.
[8] Arikant C, Berdeli A, Kilic M, et al. Polymorphisms of the ICAM-1 gene are associated with biliary atresia. Dig Dis Sci 2008;53:2000–4.
[9] Udomsinprasert W, Tenconmao T, Honsawek S, et al. +176G/T single nucleotide polymorphism of the adiponectin gene is associated with the susceptibility to biliary atresia. World J Pediatr 2012;8:328–34.
[10] Zhao R, Song Z, Dong R, et al. Polymorphism of ITGB2 gene 39-UTR +145/C/A is associated with biliary atresia. Digestion 2013;88:65–71.
[11] Davit-Spraul A, Baussan C, Hermezuz B, et al. FCPC1 gene involvement in biliary atresia with polysplenia syndrome. J Pediatr Gastroenterol Nutr 2008;46:111–2.
[12] Santos JL, Carvalho E, Bezerra JA. Advances in biliary atresia: from patient care to research. Braz J Med Biol Res 2010;43:522–7.
[13] Cheng G, Tang CS, Wong EH, et al. Common genetic variants regulating ADH3 gene expression alter biliary atresia risk. J Hepatol 2013;59:1285–91.
[14] Cui S, Leyva-Vega M, Tsai EA, et al. Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene. Gastroenterology 2013;144:1107–15.
[15] Tsai EA, Gorochowski CM, Loomes KM, et al. Replication of a GWAS signal in a Caucasian population implicates ADD3 in susceptibility to biliary atresia. Hum Genet 2014;133:235–43.
[16] Zeng S, Sun P, Chen Z, et al. Association between single nucleotide polymorphisms in the ADD3 gene and susceptibility to biliary atresia. PLoS One 2014;9:e107977.
[17] Ningappa M, So J, Glessner J, et al. The role of ARF6 in biliary atresia. PLoS One 2015;10:e0133831.
[18] Mieli-Vergani G, Vergani D. Biliary atresia. Semin Immunopathol 2009;31:371–81.
[19] Meier Y, Zodan T, Lang C, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008;14:38–45.
[20] Dixon PH, van Mil SWC, Chambers J, et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009;58:537–44.
[21] Zarenehzad M, Delghami M, Eftekhadi F, et al. Investigation of common variations of ABCB4, ATP8B1 and ABCB11 genes in patients with


to


to


to


to
progressive familial intrahepatic cholestasis. Hepat Mon 2017;17:e43500.

[22] Sangkhathat S, Laochareonsuk W, Maneechay W, et al. Variants associated with infantile cholestatic syndromes detected in extrahepatic biliary atresia by whole exome studies: a 20-case series from Thailand. J Pediatr Genet 2018;doi:10.1055/s-0038-1632395.

[23] Wildhaber BE. Biliary atresia: 50 years after the first Kasai. ISRN Surg 2012;2012:132089.

[24] Iwata R, Baur K, Steiger B, et al. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci 2011;120:287–96.

[25] Karpen AMSJ. Genetic contributors and modifiers of biliary atresia. Dig Dis 2015;33:408–14.

[26] Verkade HJ, Bezerra JA, Davenport M, et al. Biliary atresia and other cholestatic childhood diseases: Advances and future challenges. J Hepatol 2016;65:631–42.

[27] Zhang BP, Huang ZH, Chen D. Biliary atresia combined with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature. Medicine 2019;98:e15593.

[28] Sergi CM. Genetics of biliary atresia: a work in progress for a disease with an unavoidable sequela into liver cirrhosis following the failure of hepatic portoenterostomy. Liver Cirrhosis – Debates Curr Chall 2019; doi:10.5772/intechopen.85071.

[29] Hu G, He P, Liu Z, et al. Diagnosis of ABCB11 gene mutations in children with intrahepatic cholestasis using high resolution melting analysis and direct sequencing. Mol Med Rep 2014;10:1264–74.

[30] Chen Y, Gilbert MA, Grochowskis CM, et al. A genome-wide association study identifies a susceptibility locus for biliary atresia on 2p16.1 within the gene EFEMP1. PloS Genet 2018;14:e1007532.

[31] Besheer T, Araf M, El-Maksoud MA, et al. Diagnosis of cirrhosis in patients with chronic hepatitis C genotype 4: role of ABCB11 genotype polymorphism and plasma bile acid levels. Turk J Gastroenterol 2018;29:298–307.

[32] Tung NV, Lien NTK, Mai NTP, et al. Study on the association ABC2 rs927344 and MYO5B rs1815930 with congenital biliary atresia in Vietnamese population. Proc 2020 Vietnam Natl Conf Biotechnol 2020;11:724–9.

[33] Sockoian S, Castano G, Burgueno A, et al. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 2008;48:125–32.

[34] Vij M, Rela M. Biliary atresia: pathology, etiology and pathogenesis. Future Sci OA 2020;6:FSO466.

[35] Girard M, Lacaille F, Verkarre V, et al. MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillus inclusion disease. Hepatology 2014;60:301–10.

[36] Gonzalez E, Taylor SA, Davit-Spraul A, et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillus inclusion disease. Hepatology 2016;doi: 10.1002/hep.28779.

[37] Aldrian D, Vogel GF, Frey TK, et al. Congenital diarrhea and cholestatic liver disease: phenotypic spectrum associated with MYO5B mutations. J Clin Med 2021;10:481.